clinical trial · NCT07450547
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Anagram Therapeutics, Inc.·phase2·recruiting·n = 113
Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)ANG003 Dose AANG003 Dose BCreon
brief summary
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
started
Apr 24, 2026
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
May 8, 2026
official title
A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol